2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle C
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

154 Randomized controlled trial of a psychosocial digital application (THRIVE-MM) for patients living with multiple myeloma

Hermioni Amonoo, MD, MPP, MPH, Cheri Marmarosh2, Suzanne Hollman3, Katherine Holmbeck4, Tessa J Stewart5, Madison V Freese6, Upeka Samarakoon, PhD, MPH7, Nora Horick8, Jennifer S Temel9, Joseph A Greer, PhD10, Richard Newcomb, MD11, Lisa M Gudenkauf, PhD, MPH12, Emma P Keane, BA13, Galen E Switzer14, Elizabeth O'Donnell, MD15, Noopur S Raje, MD16, Andrew J. Yee, MD17, Dustin J Rabideau, PhD18, Areej R El-Jawahri, MD19
1 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States, Mass General Brigham, Boston, United States
2 Divine Mercy University, Sterling, Virginia, United States
3 Divine Mercy University, Sterling, Virginia, United States
4 Massachusetts General Hospital Cancer Center, Boston, United States
5 Massachusetts General Hospital Cancer Center, Boston, United States
6 Massachusetts General Hospital Cancer Center, Boston, United States
7 Massachusetts General Hospital Cancer Center, Boston, United States
8 Massachusetts General Hospital Cancer Center, Boston, United States
9 Harvard Medical School, Boston, United States, Massachusetts General Hospital Cancer Center, Boston, United States
10 Harvard Medical School, Boston, United States, Mass General Brigham, Boston, United States
11 Harvard Medical School, Boston, United States, Massachusetts General Hospital Cancer Center, Boston, United States
12 Dana-Farber Cancer Institute, Boston, United States, Harvard Medical School, Boston, United States, Mass General Brigham, Boston, United States
13 Mass General Brigham, Boston, United States
14 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Massachusetts General Hospital Cancer Center, Boston, United States
17 Massachusetts General Hospital Cancer Center, Boston, United States
18 Massachusetts General Hospital Cancer Center, Boston, United States
19 Harvard Medical School, Boston, United States, Massachusetts General Hospital Cancer Center, Boston, United States

Background: Patients living with multiple myeloma (MM) struggle with considerable quality of life (QOL) impairments, fatigue, and psychological distress throughout their illness course. However, few accessible and scalable interventions address the supportive care needs of these patients. We assessed the efficacy of a self-guided psychosocial digital application (app), THRIVE-MM, for improving QOL, fatigue, and psychological distress in patients living with MM.

Methods: We conducted a single-center randomized controlled trial of THRIVE-MM vs. usual care for adults living with MM. Eligible participants included patients with newly diagnosed MM receiving first line therapy, relapsed MM receiving second- or third-line therapy, or MM on maintenance therapy. Participants were randomly assigned 1:1 to THRIVE-MM or usual care, stratified by line of therapy (first line vs. second/third line vs. maintenance) and were given access to the THRIVE-MM digital app up to 8 weeks after enrollment. THRIVE-MM comprises five modules designed to improve patients’ physical and psychological symptoms via psychoeducation and evidence-based self-management skills training for behavioral change and coping skills training, delivered through interactive activities, educational games, and videos. Participants completed self-report measures at enrollment (baseline), week 8, and week 15. The primary endpoint was QOL at week 8 assessed by the Functional Assessment of Cancer Therapy (FACT)-MM. Secondary outcomes were fatigue (FACT-Fatigue), depression and anxiety symptoms (Hospital Anxiety and Depression Scale), and symptoms of posttraumatic stress disorder (PTSD Checklist). We assessed the effect of THRIVE-MM on each outcome using analysis of covariance, controlling for baseline criterion value. Next, we examined changes in outcomes over time (baseline, week 8, and week 15) using longitudinal mixed-effects models with maximum likelihood estimation for missing data. Finally, we explored whether diagnosis type (newly diagnosed vs. relapsed disease) moderated THRIVE’s effects on week 8 outcomes using pre-specified linear regression models, including interaction terms between the randomized group and diagnosis type.

Results: From 12/2023-6/2025, we enrolled 59.1% (120/203) of eligible patients (mean (SD) age=68.2 (10.0) years; 49.2% women) who were randomized to THRIVE-MM (n=60) or usual care (n=60). Mean (SD) use time for THRIVE-MM in the intervention group was 221.9 (197.1) minutes. Week 8 QOL did not differ between groups (THRIVE-MM; 125.2 vs. usual care; 125.1, p=0.977]); however, THRIVE-MM participants reported lower fatigue (40.6 v. 37.6, p=0.012) and lower depression symptoms (2.5 vs. 3.4, p=0.044) at week 8, and these group differences were sustained at week 15 (depression; B=-0.10, p=0.036; fatigue; B=0.25, p=0.021). Anxiety and post-traumatic stress symptoms did not differ between the two groups longitudinally. Finally, moderation analyses showed greater intervention-related improvements in QOL, depression, and fatigue at week 8 among participants with relapsed MM; there were no significant moderation effects among participants with newly diagnosed MM.

Conclusions: THRIVE-MM, a psychosocial digital health intervention app for patients living with MM, decreased fatigue and depression symptoms but did not improve QOL after eight weeks of app access. Patients with relapsed disease appear to benefit the most from the THRIVE-MM intervention compared to patients with newly diagnosed MM.

Hermioni Amonoo, MD, MPP, MPH: No relevant conflicts of interest to declare.